Detalhe da pesquisa
1.
Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus.
Arthritis Care Res (Hoboken)
; 74(4): 562-571, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34806342
2.
Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study.
Lancet Rheumatol
; 4(2): e113-e124, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34901885
3.
Poor Prognosis of COVID-19 Acute Respiratory Distress Syndrome in Lupus Erythematosus: Nationwide Cross-Sectional Population Study Of 252 119 Patients.
ACR Open Rheumatol
; 3(11): 804-811, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34423922
4.
Use of biologic agents and risk of tuberculosis in Brazil, a tuberculosis high-burden country.
Drugs Context
; 9: 212598, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32788921
5.
Switching of biological therapies in Brazilian patients with rheumatoid arthritis.
Future Sci OA
; 5(1): FSO355, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30652022